Chemokine-derived Peptides that Induce Immunogenic Cancer Cell Death

Value Proposition

• High cancer cell specificity by cell surface characteristics.
• High water solubility.
• Combination of oncolytic and anti-angiogenic properties.

Unmet Need

There currently are no peptides reported to have both oncolytic and anti-angiogenic activities. Additionally, drug development requires solubility in water; however, the reported oncolytic peptides, such as LTX-315, are not. Thus, there exists a need for peptides which exhibit both anti-cancer properties that are also favorable for drug development.

Technology Description

JHU researchers have developed peptides with anti-angiogenic and oncolytic properties while also being water soluble. They have developed 22 unique peptides with desirable solubility and anti-cancer properties. The researchers’ data shows that the peptides exhibit anti-angiogenic and oncolytic activity, capable of suppressing tumor growth.

Stage of Development

• In vitro studies have been conducted on the 22 peptide derivatives. Pre-clinical studies are planned.
• Looking for partners to identify a lead peptide derivative.

Data Availability: Data available upon request.

Publication:

Furukawa N, Yang W, Chao A, Patil A, Mirando A, Pandey N, Popel A. Chemokine-derived oncolytic peptide induces immunogenic cancer cell death and significantly suppresses tumor growth. Res Sq [Preprint]. 2023 Oct 3:rs.3.rs-3335225. doi: 10.21203/rs.3.rs-3335225/v1. PMID: 37886580; PMCID: PMC10602061.